Envista Holdings Corporation has recently announced the appointment of Paul Keel as CEO and a member of the board of directors effective 1 May 2024. He succeeds Amir Aghdaei, who will continue to support the transition as a senior advisor.
“It is a great honour to lead Envista at this exciting time in our deep and rich history. I know and admire the company and industry. I am thrilled to build on Envista’s strong foundation, doing ever more to serve all our stakeholders — our customers, their patients, our colleagues, our communities, and our shareholders,” said Keel.
Keel is joining Envista from Smiths Group plc, a global technology company and FTSE 100 constituent. He previously spent 16 years with 3M in various leadership roles, including group president of the Consumer Business Group, president of 3M Medical, and president of 3M’s Specialty Dental business. Preceding 3M, he held positions of increasing responsibility at GE, McKinsey & Company, and General Mills. Paul holds a BA from Carleton College and MBA from Harvard Business School.
“Paul’s strong track record as CEO of a public, diversified, global innovation company makes him the right leader for Envista at this stage in our growth journey,” said Scott Huennekens, chairman of Envista. “His pertinent combination of accelerating growth and operational excellence with his experience in the medical and oral care markets make him uniquely qualified to lead Envista in our mission to digitise, personalise, and democratise dental care.”
Envista is a global family of more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: To partner with professionals to improve lives. Envista helps its customers deliver patient care through dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists’ clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile.
Related: Henry Schein names new members to executive management committee
